NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 65,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $869,158.57. This represents a 72.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $36.56 on Thursday. The company has a 50 day simple moving average of $33.16 and a 200-day simple moving average of $34.21. The company has a market capitalization of $4.27 billion, a P/E ratio of -20.42 and a beta of 0.02. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NAMS shares. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Guggenheim increased their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Needham & Company LLC raised their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in NewAmsterdam Pharma by 84.4% in the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after buying an additional 387,698 shares during the period. Stempoint Capital LP lifted its position in shares of NewAmsterdam Pharma by 147.1% during the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock worth $5,783,000 after purchasing an additional 107,552 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of NewAmsterdam Pharma by 34.9% during the 1st quarter. California State Teachers Retirement System now owns 54,329 shares of the company’s stock worth $1,739,000 after purchasing an additional 14,053 shares during the last quarter. Maverick Capital Ltd. lifted its position in shares of NewAmsterdam Pharma by 15.4% during the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock worth $69,987,000 after purchasing an additional 292,176 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of NewAmsterdam Pharma by 35.6% during the 1st quarter. Sei Investments Co. now owns 55,637 shares of the company’s stock worth $1,781,000 after purchasing an additional 14,597 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.